AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Biovail drug staves off generics
Biovail's top-selling hypertension and angina treatment, Tiazac, will be listedin the FDA's "Orange Book." That could fend off generic rivals by 30 months. Biovail's shares jumped 4.11, or 10%, to 44.33. Shares of Forest Laboratories, which markets Tiazac in the U.S., gained 3.19, or 5%, to 65.75. Andrx, which plans to launch a generic Tiazac in the spring, accused Biovail of a "transparent ploy" to illegally ex
tend its patent. The generic-drug maker said its drug isn't covered by Biovail's patent.
Forest Labs also said its Memantine Alzheimer's disease treatment could be launched by 2003 if either of two late-stage …